Annovis Bio, Inc.
- Open
- 1.72
- Day high
- 1.76
- Day low
- 1.70
- Prev close
- 1.69
- Volume
- 360K
- Mkt cap
- $61M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 19.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $143K over the last 3 months (3 open-market buys, 0 sales)
- 🏛Institutions accumulating (13F)
Annovis Bio, Inc. (ANVS) is a Healthcare company listed on NYSE. The stock is down 32% over the past year. Over the trailing 3 months, insiders filed 3 open-market buys and 0 sales (SEC Form 4).
Annovis Bio, Inc. (ANVS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ANVS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | $-0.40 | $-0.63 | -59.5% | — | — |
| Mar 16, 2026 | $-0.31 | $-0.39 | -26.5% | — | — |
| Nov 12, 2025 | $-0.36 | $-0.37 | -2.8% | — | — |
| Aug 12, 2025 | $-0.36 | $-0.32 | +11.1% | — | — |
| Mar 21, 2025 | $-0.38 | $-0.43 | -13.2% | — | — |
| Nov 8, 2024 | $-0.53 | $-0.97 | -83.0% | — | — |
| Aug 14, 2024 | $-0.63 | $-0.44 | +30.2% | — | — |
| Mar 29, 2024 | $-1.35 | $-1.09 | +19.3% | — | — |
| Aug 15, 2023 | $-1.14 | $-1.07 | +6.1% | — | — |
| May 11, 2023 | $-0.85 | $-1.19 | -40.0% | — | — |
| May 4, 2022 | $-0.58 | $-0.72 | -24.1% | — | — |
| Mar 2, 2022 | $-0.25 | $-0.75 | -200.0% | — | — |
ANVS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 21, 2026 | Hoffman Michael Bdirector | Buy | 2,562 | $1.75 |
| May 21, 2026 | Hoffman Michael Bdirector | Buy | 54,933 | $1.90 |
| May 21, 2026 | Hoffman Michael Bdirector | Buy | 18,849 | $1.80 |
| Apr 3, 2026 | Hoffman Michael Bdirector | Buy | 713,800 | $2.10 |
| Dec 8, 2025 | Hoffman Michael Bdirector | Buy | 30,000 | $4.34 |
| Dec 8, 2025 | Hoffman Michael Bdirector | Buy | 15,000 | $4.24 |
| Nov 25, 2025 | Hoffman Michael Bdirector | Buy | 9,200 | $3.85 |
| Nov 25, 2025 | Hoffman Michael Bdirector | Buy | 415 | $4.14 |
| Nov 25, 2025 | Hoffman Michael Bdirector | Buy | 28,096 | $4.15 |
| Nov 25, 2025 | Hoffman Michael Bdirector | Buy | 1,489 | $4.13 |
| Nov 21, 2025 | Hoffman Michael Bdirector | Buy | 10,000 | $3.50 |
| Nov 18, 2025 | Hoffman Michael Bdirector | Buy | 15,000 | $2.11 |
| Nov 12, 2025 | Bruck Claudinedirector | Option | 7,142 | $0.14 |
| Nov 12, 2025 | Maccecchini Maria-Luisadirector, officer: President & CEO | Buy | 97,561 | $2.05 |
| Nov 12, 2025 | Hoffman Michael Bdirector | Buy | 975,610 | $2.05 |
Source: ANVS SEC Form 4 filings, latest May 21, 2026. For informational purposes only — not investment advice.
See the full ANVS insider & 13F page →Annovis Bio, Inc. company profile
Overview
Annovis Bio, Inc. (NASDAQ:ANVS) is a clinical-stage biotechnology company founded in 2008 and headquartered in Berwyn, Pennsylvania. The company went public in January 2020 and focuses on developing novel drug treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Annovis operates as a drug platform company, meaning it develops a portfolio of compounds that can potentially treat multiple neurological conditions through similar mechanisms of action.
Business
Annovis Bio operates in the biotechnology sector, specifically focusing on neurodegeneration drug development. Neurodegeneration refers to the progressive loss of structure and function of neurons in the brain, which leads to conditions like Alzheimer's disease, Parkinson's disease, and other forms of dementia. The biotechnology industry involves using biological processes and living organisms to develop pharmaceutical products, which typically requires extensive research, clinical testing, and regulatory approval before commercialization. The company's primary focus is developing Buntanetap, an orally administered drug that has completed Phase 2a clinical trials for treating both Alzheimer's disease and Parkinson's disease. Buntanetap works by targeting the translation of neurotoxic proteins that are believed to cause nerve cell death in these conditions. The drug is also being tested for Alzheimer's disease in Down Syndrome patients and other chronic neurodegenerative disorders. Beyond Buntanetap, Annovis has two other compounds in development. ANVS405 is being developed to protect against traumatic brain injury and stroke, while ANVS301 is in Phase I clinical trials aimed at increasing cognitive capability in later stages of Alzheimer's disease and dementia. The company's approach involves targeting the underlying mechanisms that cause multiple neurodegenerative diseases rather than treating symptoms, which could potentially address several conditions with a single therapeutic platform.
Revenue model
As a clinical-stage biotechnology company, Annovis Bio currently generates no revenue from product sales, as evidenced by zero revenue across all reported periods. The company operates on a research and development model typical of early-stage biotech firms, where significant upfront investment is required for drug development with the expectation of future revenue once products receive regulatory approval and reach market. The company's future revenue model would likely involve several streams once its drugs are approved. These could include direct product sales to hospitals and healthcare systems, licensing agreements with larger pharmaceutical companies for manufacturing and distribution rights, and potentially royalty payments from partnership deals. The paying customers would primarily be healthcare providers, insurance companies, and patients requiring treatment for neurodegenerative diseases. Several factors could significantly impact Annovis Bio's future profitability. Positive clinical trial results would increase the likelihood of regulatory approval and market success, while negative results could eliminate entire revenue streams. The competitive landscape in neurodegeneration treatments is intense, with major pharmaceutical companies investing billions in similar research. Regulatory approval timelines and requirements from the FDA can significantly affect time-to-market and development costs. Additionally, the company's ability to secure partnerships with larger pharmaceutical companies could provide crucial funding and distribution capabilities, while healthcare reimbursement policies will ultimately determine patient access and pricing power for approved treatments.
Competitive moat
Annovis Bio's competitive moat is currently limited and primarily relies on its intellectual property portfolio and early-mover advantage in its specific therapeutic approach. The company's main potential moat lies in its platform technology that targets the translation of neurotoxic proteins, which could differentiate it from competitors focusing on other mechanisms like amyloid plaques or tau proteins in Alzheimer's research. However, the biotechnology industry is characterized by weak moats due to several factors. Patent protection, while important, eventually expires and can be challenged or worked around by competitors. The regulatory approval process, while creating temporary barriers, does not prevent other companies from developing similar or superior treatments. Large pharmaceutical companies possess significantly greater resources for research and development, clinical trials, and regulatory processes, which could allow them to outcompete smaller biotech firms. The primary competitive threats come from established pharmaceutical giants like Roche, Pfizer, and Biogen, which have extensive resources and existing market presence in neurology treatments. Additionally, the recent approval of new Alzheimer's treatments like Aduhelm (though controversial) demonstrates that the field is advancing rapidly. Annovis faces the constant risk that larger competitors could develop more effective treatments, acquire competing technologies, or simply out-execute in clinical trials and commercialization. The company's survival largely depends on achieving positive clinical trial results and either partnering with or being acquired by a larger pharmaceutical company.
Risks & safety
Annovis Bio presents significant financial risks typical of clinical-stage biotechnology companies, with limited margin of safety for investors. • Cash burn and solvency: The company burned through approximately $21.9 million in operating cash flow during 2024, with current cash and short-term investments of $22.2 million as of Q1 2025, suggesting roughly one year of runway at current burn rates. • Debt levels: The company maintains a debt-free balance sheet with a debt-to-equity ratio of 0.0, which eliminates bankruptcy risk from debt obligations but doesn't address the cash burn issue. • Valuation metrics: With a market capitalization of approximately $62.6 million and no revenue, traditional valuation metrics are not applicable. The company trades at significant multiples to book value, indicating high speculative premium. • Other considerations: The company's current ratio of 10.68 indicates strong short-term liquidity, but this is primarily due to low current liabilities rather than strong cash generation. The negative return on equity of -230% reflects the substantial losses relative to shareholder equity.
Recent development
Based on the available financial data, Annovis Bio has been progressing through clinical trials for its lead compound Buntanetap over the past few years. The company completed Phase 2a clinical trials for both Alzheimer's disease and Parkinson's disease applications of Buntanetap, representing a significant milestone in its development program. The company has expanded its pipeline beyond the original Buntanetap program by advancing ANVS301 into Phase I clinical trials for cognitive enhancement in late-stage Alzheimer's and dementia patients. Additionally, the development of ANVS405 for traumatic brain injury and stroke protection represents a strategic expansion into acute neurological conditions beyond chronic neurodegenerative diseases. The financial trajectory shows the typical pattern of a clinical-stage biotech company, with increasing research and development expenses as trials progress. The company's cash position has declined from over $28 million in 2022 to approximately $22 million in early 2025, reflecting the substantial costs associated with advancing multiple compounds through clinical development. The lack of revenue generation and increasing operating losses underscore the company's dependence on successful clinical outcomes and additional financing to continue operations.
ANVS company profile · for informational purposes only — not investment advice.
Track ANVS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free